The innovators at Immunovia, Inc. have developed IMMray® PanCan-d, the first blood test dedicated to the early detection of pancreatic cancer in individuals at risk for developing familial or hereditary pancreatic ductal adenocarcinoma (PDAC). Pancreatic cancer is a low incidence disease with a high mortality rate. The survival rate for those diagnosed in late stages is tragically low at 3%, but w
ith early detection, the survival rate jumps to 44%. The goal of the IMMray PanCan-d test is to detect pancreatic cancer at earlier stages (stage I and II), when interventions and treatments can be most effective. This test is not just an advancement in science, but a chance for individuals to have a brighter future. The science behind the IMMray® PanCan-d test is complex, but what it provides for patients at risk is simple: Hope. The IMMray® PanCan-d test is dedicated to one simple goal: early detection. With early detection, we can possibly change the outcome of this devastating disease for individuals at risk. IMMray® PanCan-d measures 9 biomarkers (mostly proteins) that, when combined in an algorithm, may indicate the presence of pancreatic cancer. It’s another powerful tool for looking for pancreatic cancer in at-risk patients, assisting with the proactive surveillance of pancreatic cancer. Imagine a world where pancreatic cancer can be caught before it has a chance to spread and cause irreparable damage. is working hard to make that world a possible reality.
Want to learn more about the IMMray® PanCan-d test? Visit immunoviainc.com. References:
American Cancer Society. Cancer Facts and Figures 2023. Brand RE, Persson J, Bratlie SO et al. Clin Transl Gastroenterol. 2022;13(3):e00468.
